Project description:Gene signature determination of the effect of a new bromodomain inhibitor among a representative set of leukemic cell lines OTX015 vs. DMSO and JQ1 vs. DMSO
Project description:4 lymphoma cell lines (DOHH2, OCILy10, TMD8 and Toledo) have been treated with DMSO, CB103, NEO02734 or OTX015. The transcriptome has been sequenced after 6hrs from the treatment. The gene expression levels have been compared in order to elucidate the differencies and similarities for the different drugs compare to DMSO (control group).
Project description:We performed RNA-sequencing on erythroid cell lines treated with DMSO or JQ1. We found that JQ1 induces erythropoiesis and specifically upregulated fetal and embryonic globin genes at the beta globin locus.
Project description:We performed RNA-sequencing on erythroid cell lines treated with DMSO or JQ1. We found that JQ1 induces erythropoiesis and specifically upregulated fetal and embryonic globin genes at the beta globin locus.
Project description:RNAseq is performed (50bp single end reads) on SW480, HT-29, HCT-15, HCT-116, COLO 205, and COLO 320 cell lines after DMSO or JQ1 treatment
Project description:To understand the molecular curcuits perturbed by BET bromodoman inhibtion we obtained gene expression profiling of five DLBCL cell lines, SU-DHL6, OCI-Ly1, OCI-Ly4, Toledo and HBL-1, which were treated with either 500nM JQ1 or DMSO for 0,2,6,12,24 and 48hr. RNA samples from five DLBCL cell lines at baseline (time 0) or following treatment with 500nM of JQ1 or vehicle (DMSO) alone for 2, 6, 24 or 48 hours were profiled in triplicate on Affymetrix Human Gene 1.0 ST Array.
Project description:The objective was to investigate the impact of JQ1, a bromodomain inhibitor, on two cell lines of HPV+ HNSCC by comparing it to a control group that did not receive any treatment (DMSO).
Project description:The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D). Samples were treated for 72hr and run in triplicate.
Project description:Transcriptional profiling of the human pancreatic cancer cell line SUIT-2 that were infected with a GFP encoding adenoviral construct based on Human Adenovirus 5 and treated with epigenetic modifiers I-bet-762, NEO27034 or OTX015 compared to uninfected and untreated cells. Cells were infected with 1pfu AdWTGFP in serum free media for 2 hours. Cells were then washed and cultured in media containing 2% FBS for 10 hours. Cells were then treated with I-bet-762, NEO27034, OTX015 or DMSO in media containing 2% FBS for 12 hours. Infected GFP+ cells were isolated by FACS. GFP+ and control cells were processed for RNA-seq.
